Dare Bioscience (DARE) Asset Utilization Ratio (2014 - 2026)
Dare Bioscience's (DARE) quarterly Asset Utilization Ratio came in at 0.04 in Q2 2026, up 3980.82% on a YoY basis from 0.0 in Q2 2025, and up 33.42% quarter-over-quarter from 0.03 in Q4 2025.
Analysis
Dare Bioscience (DARE) Asset Utilization Ratio (2014 - 2026) Analysis & Trends
Dare Bioscience (DARE) has reported Asset Utilization Ratio for 10 consecutive years, with 0.04 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Utilization Ratio rose 3980.82% year-over-year to 0.04; the trailing twelve-month figure through Jun 2026 stood at 0.04 (up 3980.82% YoY), and the FY2025 full-year result was 0.04, up 8270.01% from the prior year.
- Asset Utilization Ratio advanced to 0.04 in Q2 2026 per DARE's latest filing, from 0.03 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.27 in Q1 2023 and bottomed at 0.0 in Q3 2025.
- Historically, Asset Utilization Ratio has averaged 0.1 across 5 years, with a median of 0.09 in 2024.
- The widest YoY moves for Asset Utilization Ratio: up 6588.35% in 2025, down 102.89% in 2025.
- Over 5 years, Asset Utilization Ratio stood at 0.21 in 2022, then plunged by 42.91% to 0.12 in 2023, then slumped by 99.6% to 0.0 in 2024, then surged by 6588.35% to 0.03 in 2025, then soared by 33.42% to 0.04 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.04, 0.03, and 0.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 0.33 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 0.54 |
| 10 | Dare Bioscience | 10.92 Mn | -1.70 Mn | -132,343.00 | 0.04 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.04 |
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.09 |
| Jun 30, 2024 | 0.16 |
| Mar 31, 2024 | 0.16 |
| Dec 31, 2023 | 0.12 |
| Sep 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.27 |
| Dec 31, 2022 | 0.21 |
| Sep 30, 2022 | 0.20 |
| Jun 30, 2022 | 0.20 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | 0.06 |
| Jun 30, 2021 | 0.21 |
| Jun 30, 2017 | 0.22 |
| Mar 31, 2017 | 0.24 |